Healthcare legislation boosts future of cancer care services

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging.

BALTIMORE-Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging, according to a presenter at the 2010 Association of Community Cancer Centers meeting.

The new legislation will spend $940 billion over ten years to expand private insurance coverage and expand the privately insured patient population including those who require cancer care, said Matt Brow, vice president of government relations and public policy for US Oncology, based in the Woodlands, Tex.

Mr. Brow pointed out some of the provisions that directly affect oncology care:

Practices can voluntarily participate in accountable care organizations (ACOs) that will manage and coordinate care across settings. Lower cost or the use of equally effective regimens will be rewarded. ACOs can consist of physician groups, networks of physician groups, and joint ventures between a hospital and physicians.
The CMS Innovation Center, a testing ground for new payment models, will align nationally recognized, evidence-based guidelines of cancer care with Medicare payment incentives for treatment planning and follow-up care for Medicare beneficiaries.
Insurance company coverage of routine costs associated with participation in a clinical trial, which may increase trial participation.
New fees on medical device manufacturers such as higher costs for such equipment as linear accelerators.

Source: "Healthcare Reform: How Does Oncology Fare?,"

www.accc-cancer.org

Recent Videos
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content